RAHIMA AFGHAN: Open Payments
NPI 1023060449 · MURRIETA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,205 in 50 payments from 14 companies in 2025. Trend: 2023 $1,588 · 2024 $1,383 · 2025 $1,205
Food & beverage: $1,205
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $249 |
| ABBVIE INC. | 11 | $234 |
| Otsuka America Pharmaceutical, Inc. | 7 | $143 |
| E.R. Squibb & Sons, L.L.C. | 5 | $128 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $123 |
| Lundbeck LLC | 4 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Luye Pharma (USA) Ltd. | 1 | $23 |
| Biogen, Inc. | 1 | $22 |
Products named: INGREZZA, VRAYLAR, REXULTI, COBENFY, CAPLYTA, TRINTELLIX, ABILIFY MAINTENA, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
